Zydus Cadila has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets (US RLD Belviq Tablets), 10 mg.
The drug is used together with diet and exercise to treat obesity. It will be manufactured at the group's formulations manufacturing facility at SEZ.
The group now has 278 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)